Clinical Trials on Myositis Ossificans in United Kingdom

Total 368 results

Ipsen

Active, not recruiting

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. (PIVOINE)

Fibrodysplasia Ossificans Progressiva (FOP)

United States, France, Australia, Argentina, Italy, Canada, Sweden, United Kingdom, Brazil, Spain
Clementia Pharmaceuticals Inc.

Completed

An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects

Fibrodysplasia Ossificans Progressiva

United States, France, United Kingdom
Clementia Pharmaceuticals Inc.

Completed

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. (MOVE)

Fibrodysplasia Ossificans Progressiva

United States, Canada, France, Australia, Argentina, Brazil, Italy, Japan, Spain, Sweden, United Kingdom
Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva (LUMINA-1)

Fibrodysplasia Ossificans Progressiva

United States, Spain, Canada, France, Poland, Italy, Netherlands, United Kingdom
Clementia Pharmaceuticals Inc.
Ipsen

Recruiting

A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). (FALKON)

Fibrodysplasia Ossificans Progressiva

United States, Korea, Republic of, Belgium, China, Sweden, France, Japan, Argentina, Australia, Brazil, Canada, Italy, Spain, United Kingdom, Mexico, Colombia, Netherlands, Germany, Portugal
Clementia Pharmaceuticals Inc.

Terminated

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects

Fibrodysplasia Ossificans Progressiva

United States
Clementia Pharmaceuticals Inc.

Completed

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva

United States, Argentina, Australia, France, United Kingdom
Clementia Pharmaceuticals Inc.

Completed

A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva

United States, Argentina, Australia, France, United Kingdom, Italy
Clementia Pharmaceuticals Inc.

Completed

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

Fibrodysplasia Ossificans Progressiva

United States
Incyte Corporation

Recruiting

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva (Progress)

Fibrodysplasia Ossificans Progressiva (FOP)

United States, France, Korea, Republic of, Spain, Italy, United Kingdom, Russian Federation, China, Australia, Brazil, Mexico, New Zealand, Argentina, Canada, Netherlands, Turkey, Chile, Germany, South Africa, Portugal
Ipsen

Completed

An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.

Fibrodysplasia Ossificans Progressiva

United States
Novartis Pharmaceuticals

Completed

Urine Sample Collection From FOP Patients (FOP)

Fibrodysplasia Ossificans Progressiva

United States
Regeneron Pharmaceuticals

Recruiting

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA)

Fibrodysplasia Ossificans Progressiva

Japan, United States, Korea, Republic of, Spain, France, Australia, United Kingdom, China, Poland, Malaysia, Italy, Finland, Hong Kong, South Africa, Chile, Brazil, Netherlands, Colombia
Amsterdam UMC, location VUmc
AstraZeneca; Brigham and Women's Hospital; University of Oxford; Klinikum Garmisch-Patenkirchen and other collaborators

Recruiting

Saracatinib Trial TO Prevent FOP (STOPFOP)

Fibrodysplasia Ossificans Progressiva

Germany, Netherlands, United Kingdom
The International FOP Association

Recruiting

The Fibrodysplasia Ossificans Progressiva (FOP) Connection Registry

Fibrodysplasia Ossificans Progressiva (FOP)

United States
Regeneron Pharmaceuticals

Completed

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva (FOP)

United States
Richard Barohn, MD

Completed

Arimoclomol in Sporadic Inclusion Body Myositis

Inclusion Body Myositis

United States, United Kingdom
ZevraDenmark
University College, London; University of Kansas Medical Center

Terminated

Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

Inclusion Body Myositis

United States, United Kingdom
ZevraDenmark
University College, London; University of Kansas Medical Center

Completed

Study of Arimoclomol in Inclusion Body Myositis (IBM)

Inclusion Body Myositis

United States, United Kingdom
University of Kansas Medical Center

Completed

Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis

Inclusion Body Myositis | Sporadic Inclusion Body Myositis

United States
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis

United States
Novartis Pharmaceuticals

Completed

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis (BYM338)

Sporadic Inclusion Body Myositis (sIBM)

United States
Phoenix Neurological Associates, LTD

Unknown

Natalizumab in Inclusion Body Myositis (IBM) (IBM-NAT)

Inclusion Body Myositis (IBM)

United States
University of Manchester
Karolinska Institutet; Eli Lilly and Company; Clinical Trials Unit, Manchester

Completed

JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM (MYOJAK)

Idiopathic Inflammatory Myopathies

United Kingdom
University of Kansas Medical Center
BioSensics

Recruiting

Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time

Inclusion Body Myositis

United States
Yale University

Completed

Establishing Muscle Impedance Parameters With Electrical Impedance Myography

Inclusion Body Myositis | IBM

United States
Johns Hopkins University

Completed

Study of Pioglitazone in Sporadic Inclusion Body Myositis

Nervous System Diseases | Muscular Diseases | Neuromuscular Diseases | Myositis | Musculoskeletal Disease | Inclusion Body Myositis

United States
Abcuro, Inc.
Syneos Health

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Inclusion Body Myositis

United States, Australia, Belgium, France, Canada, Germany, United Kingdom
Royal Brompton & Harefield NHS Foundation Trust
University College London Hospitals; Imperial College London; University of East...

Completed

Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD (RECITAL)

Interstitial Lung Disease | Scleroderma | Idiopathic Inflammatory Myositis | Mixed Connective Tissue Disease

United Kingdom
Phoenix Neurological Associates, LTD

Completed

Lithium in Inclusion Body Myositis (IBM) (Li-IBM)

Inclusion Body Myositis

United States
Novartis Pharmaceuticals

Completed

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

Sporadic Inclusion Body Myositis

United States, Belgium, Italy, Australia, Netherlands, Switzerland, France, United Kingdom, Denmark, Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients (RESILIENT)

Sporadic Inclusion Body Myositis

United States, Belgium, Italy, Australia, Netherlands, Switzerland, France, United Kingdom, Denmark, Japan
University of Kansas Medical Center

Active, not recruiting

Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells

Inclusion Body Myositis

United States
Washington University School of Medicine
Amgen

Completed

Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis

Inclusion Body Myositis

United States
University of Manchester
King's College Hospital NHS Trust; Northern Care Alliance NHS Foundation Trust and other collaborators

Active, not recruiting

MYOPROSP - a Prospective Cohort Study in Myositis (MYOPROSP)

Myositis | Idiopathic Inflammatory Myopathy

United Kingdom
National Institute of Neurological Disorders and...

Completed

Alemtuzumab to Treat Sporadic Inclusion Body Myositis

Myositis, Inclusion Body

United States
University of California, Irvine
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Active, not recruiting

Sporadic Inclusion Body Myositis Natural History Study (INSPIRE-IBM)

Inclusion Body Myositis | Sporadic Inclusion Body Myositis

United States
St George's, University of London
Wings for Life; Neurosciences Research Foundation

Completed

Injured Spinal Cord Pressure Evaluation Study - Transverse Myelitis (ISCoPE-TM)

Transverse Myelitis

United Kingdom
Alizyme

Completed

Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis

Mucositis

United Kingdom
National Institute of Neurological Disorders and...

Completed

Immune Abnormalities in Sporadic Inclusion Body Myositis

Myositis | Sporadic | Inclusion Body

United States
Mundipharma Research Limited

Terminated

A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain (BUP1501)

Chemotherapy Induced Mucositis | Mouth Pain

Denmark, United Kingdom
Northern Care Alliance NHS Foundation Trust

Active, not recruiting

Investigating Genes in Patients With Polymyositis and Dermatomyositis (UKMYONET)

Myositis

United Kingdom
University of Kansas Medical Center
The Perron Institute

Recruiting

Phase III Trial of Sirolimus in IBM

Inclusion Body Myositis

United States, Australia
Biotec Pharmacon ASA

Completed

The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients

Oral Mucositis

Germany, United Kingdom
Abide Therapeutics

Completed

Central Pain Study for ABX-1431

Multiple Sclerosis | Neuromyelitis Optica Spectrum Disorder | Transverse Myelitis | Longitudinally Extensive Transverse Myelitis

United Kingdom
National Institute of Neurological Disorders and...

Completed

Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies

Dermatomyositis | Polymyositis | Inclusion Body Myositis

United States
University of Warwick
Northern Care Alliance NHS Foundation Trust; University Hospitals Coventry... and other collaborators

Unknown

Diagnostic Accuracy of MR in Myositis

Muscular Disorders, Atrophic | Myositis

United Kingdom
National Institute of Environmental Health Sciences...

Active, not recruiting

Environmental Risk Factors for Myositis in Military Personnel

Myositis | Dermatomyositis | Inclusion Body Myositis | Adult Polymyositis

United States
Nationwide Children's Hospital
Parent Project Muscular Dystrophy

Completed

Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis

Becker Muscular Dystrophy | Sporadic Inclusion Body Myositis

United States
National Institute of Environmental Health Sciences...

Recruiting

Adult and Juvenile Myositis

Dermatomyositis | Polymyositis | Inclusion Body Myositis

United States

Clinical Trials on Myositis Ossificans in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations